Exam 2 - Colorectal Cancer Weddle (not done)

Question 1

colorectal cancer is the ____ leading cancer in incidence and death in men and women

Answer 1

3rd

Question 2

what is familial adenomatous polyposis (FAP)?

Answer 2

disorder where there is mutation of adenomatous polyposis coli (APC) located on chromosome 5; it is a risk factor for colorectal cancer

Question 3

> ___ % of colorectal cancers are adenocarcinomas

Answer 3

> 95%

Question 4

additional testing for CRC: we can test for __________ __________ or test for loss of genes involved in DNA mismatch repair

Answer 4

microsatellite instability (MSI)

Question 5

dMMR or MSI-H tumor predicts a __________ benefit from adjuvant 5-FU based therapy for stage ___ disease

a. decreased; stage III
b. decreased; stage II
c. increased; stage III
d. increased; stage II

Answer 5

b. decreased; stage II

Question 6

stage ___ CRC pts with dMMR or MSI-H disease _____ _____ from adjuvant 5-FU

a. III; can benefit
b. III; can’t benefit
c. IV; can benefit
d. IV; can’t benefit

Answer 6

a. III; can benefit

Question 7

T or F: all pts with a colon cancer diagnosis should be tested for mismatch repair or microsatellite instability

Answer 7

T

Question 8

is radiation therapy used mainly for colon or rectal cancer?

Answer 8

rectal

Question 9

localized therapy for stage I and II CRC

Answer 9

-surgery alone (partial or total colectomy + lymph nodes)
-stage II high risk can consider chemo

Question 10

T or F: stage II CRC with MSI-H or dMMR will benefit from chemotherapy

Answer 10

F

Question 11

what drugs are in FOLFOX? (3)

Answer 11

5-FU
leucovorin
oxaliplatin

Question 12

what drugs are in CapeOX? (2)

Answer 12

capecitabine
oxaliplatin

Question 13

is chemotherapy indicated for stage III CRC?

Answer 13

yes

Question 14

T or F: FOLFOX is indicated in average risk stage II CRC pts

Answer 14

F (for intermediate/high risk stage II)

Question 15

T or F: bevacizumab, cetuximab, panitumumab, and irinotecan play a role in chemotherapy for stage III disease

Answer 15

F

Question 16

stage III colon cancer: what are the two regimens for “low risk” pts from the IDEA trial?

a. CapeOx for 3 months
b. FOLFOX for 3-6 months
c. CapeOx for 3-6 months
d. FOLFOX for 6 months

Answer 16

a. CapeOx for 3 months
b. FOLFOX for 3-6 months

Question 17

stage III colon cancer: what are the two regimens for “high risk” pts from the IDEA trial?

a. CapeOx for 3 months
b. FOLFOX for 3-6 months
c. CapeOx for 3-6 months
d. FOLFOX for 6 months

Answer 17

c. CapeOx for 3-6 months
d. FOLFOX for 6 months

Question 18

which of the following is FALSE about FOLFOX?

a. requires port
b. 2-day pump
c. increased hand foot syndrome and diarrhea
d. more infusions overall

Answer 18

c. increased hand foot syndrome and diarrhea

(this is CapeOx)

Question 19

which of the following is TRUE about CapeOx?

a. requires port
b. 2-day pump
c. increased myelosuppression and mouth sores
d. less infusions overall

Answer 19

d. less infusions overall

Question 20

which regimen increases myelosuppression and mouth sores?

a. FOLFOX
b. CapeOx

Answer 20

a. FOLFOX

Question 21

which regimen increases risk of hand foot syndrome and diarrhea?

a. FOLFOX
b. CapeOx

Answer 21

b. CapeOx

Question 22

which regimen requires an infusion pump that you take home?

a. FOLFOX
b. CapeOx

Answer 22

a. FOLFOX

Question 23

T or F: pembrolizumab and nivolumab have shown benefit in the metastatic colon cancer setting

Answer 23

T

Question 24

T or F: KRAS mutations predict lack of response to anti-EGFR mAbs

Answer 24

T

Question 25

if someone received FOLFOX chemotherapy, what would be the 2nd line tx option if they progress?

Answer 25

FOLFIRI

Question 26

which pts is FOLFIRINOX usually for?

Answer 26

young, robust pts

Question 27

FOLFIRINOX drugs (4)

Answer 27

5-FU
leucovorin
irinotecan
oxaliplatin